ETS variant transcription factor 2 (ETV2)

ETS variant transcription factor 2 (ETV2) is a sequence-specific DNA-binding transcription factor of the ETS family, functioning as a master regulator of hematoendothelial development. ETV2 is crucial for specifying vascular endothelial and blood progenitor cell lineages during embryogenesis and is not typically expressed in mature endothelium. In experimental contexts, forced expression of ETV2 is sufficient to directly reprogram fibroblasts and other somatic cells into functional endothelial cells, making it a promising tool for regenerative approaches aiming at vascular tissue engineering and therapy for ischemic conditions. ETV2 acts as a pioneer transcription factor, opening closed chromatin regions and establishing pro-endothelial gene programs, often in cooperation with co-factors such as FOXC2. It regulates downstream targets including FLK1 (KDR), FLT1, GATA2, TIE2, CD31, and others involved in endothelial identity[1][2][3][4][6]. Diseases clearly associated with ETV2 mutations are rare, but its modulation is implicated in hypoplastic left heart syndrome and impaired angiogenic capacity. No drugs currently exist that selectively target ETV2. The main therapeutic utility lies in gene/cell-based strategies rather than small molecules or antibodies. Safety concerns for therapeutic use focus on risks tied to non-physiological cell reprogramming and potential disruption of developmental signaling when ETV2 is ectopically activated.

Other names

ETV2ER71ETSRP71Ets-related protein 71ets variant gene 2ETS translocation variant 2